BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors. 2018

Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
School of Pharmaceutical Science, Jiangnan University, Wuxi, China.

As serine/threonine kinase, the cyclin dependent kinase 2 (CDK2) is a promising target for various diseases such as cerebral hypoxia, cancer, and neurodegenerative diseases. Here we reported the structure-based synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as CDK2 inhibitors, which exhibited potent CDK2 inhibitory activities, as well as anticancer activities in low concentration against two human cancer cell lines (MCF-7 and HCT116). In particular, compounds 11a and 11f (IC50 values of 0.11 and 0.09 μM for CDK2, respectively) have demonstrated significantly inhibitory potency against CDK2 and have showed great inhibitory activities against MCF-7 and HCT116 cell lines.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011799 Quinazolines A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. Quinazoline
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051357 Cyclin-Dependent Kinase 2 A key regulator of CELL CYCLE progression. It partners with CYCLIN E to regulate entry into S PHASE and also interacts with CYCLIN A to phosphorylate RETINOBLASTOMA PROTEIN. Its activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P27 and CYCLIN-DEPENDENT KINASE INHIBITOR P21. Cdk2 Protein Kinase,CDK2 Protein,Cdc2-Related Protein Kinase,p33cdk2 Kinase,Cdc2 Related Protein Kinase,Cyclin Dependent Kinase 2

Related Publications

Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Synthesis and biological evaluation of novel 5,6-dihydrobenzo[h]quinazoline derivatives as FLT3 inhibitors.
April 2022, Chemical biology & drug design,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Synthesis and biological evaluation of novel pteridin-7(8H)-one derivatives as potent CDK2 inhibitors.
May 2023, Bioorganic & medicinal chemistry letters,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
March 2010, European journal of medicinal chemistry,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
December 2021, European journal of medicinal chemistry,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Design, synthesis and biological evaluation of novel quinazoline derivatives as immune checkpoint inhibitors.
May 2024, Bioorganic & medicinal chemistry letters,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors.
November 2023, Bioorganic chemistry,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Quinazoline-4(3H)-one derivatives as novel and potent inhibitors of soluble epoxide hydrolase: Design, synthesis and biological evaluation.
June 2020, Bioorganic chemistry,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Synthesis and biological evaluation of novel quinazoline-4-piperidinesulfamide derivatives as inhibitors of NPP1.
March 2018, European journal of medicinal chemistry,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
April 2021, Future medicinal chemistry,
Xiaoxia Hu, and Hui Zhao, and Youzhi Wang, and Zhan Liu, and Bainian Feng, and Chunlei Tang
Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents.
January 2011, Scientia pharmaceutica,
Copied contents to your clipboard!